Yousuf Gaffar, MD
Hematology & Oncology · Denver, CONPI 1891798914
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $640,749 of the $963,418 with a category attached, or 66.5%. 60 manufacturers reported payments, led by Rigel Pharmaceuticals, Inc. at 24.4% of the total. Reporting peaked in 2019 at $294,974 and has fallen 97.0% since, to $8,774 in 2025. Among hematology & oncology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,126 payments — averaging $855.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rigel Pharmaceuticals, Inc.$235K
- E.r. Squibb & Sons, L.L.C.$224K
- Exelixis Inc.$142K
- AstraZeneca$101K
- Novartis$52K
- Dova Pharmaceuticals$49K
- plus $160K from 54 others
Across 569 payments — averaging $1543.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$466K
- Incyte Corporation$150K
- Mirati Therapeutics, Inc.$139K
- AstraZeneca$90K
- CTI Biopharma Corp.$13K
- Pfizer$8K
- plus $13K from 4 others
What the payments were for
- Consulting fees$179,11119%
- Speaking & faculty fees$640,74967%
- Travel & lodging$119,26712%
- Food & beverage$23,5772%
- Education$2490%
- Other$4660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$963,418 in reported general payments places this provider in the 95th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 12 | $159,391 |
| EliquisApixaban | 33 | $26,978 |
| XareltoRivaroxaban | 12 | $14,798 |
| Oxycodone Hcl | 16 | $430 |
| Gabapentin | 17 | $170 |
| Letrozole | 11 | $132 |
| Dexamethasone | 14 | $89 |
| Prednisone | 12 | $83 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $100,604 | $159,39112 claims |
| PfizerEliquis | $295 | $26,97833 claims |
| Johnson & JohnsonXarelto | $407 | $14,79812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 169 hematology & oncology providers in Colorado.
Other hematology & oncology in Denver
- Amy SchmidtDenver$2.8M
- Robert RifkinDenver$270K
- Mabel MardonesDenver$149K
- Peter ForsbergDenver$147K
- Peter McSweeneyDenver$126K
- Alireza EghtedarDenver$96K
- Jeffrey MatousDenver$93K
- Tara GregoryDenver$67K
- Michael TeesDenver$56K
- Marcello RottaDenver$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.